Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

[1]  A. Prat,et al.  Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. , 2022, Cancer treatment reviews.

[2]  Adrian V. Lee,et al.  Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis , 2022, Nature Cancer.

[3]  H. Denys,et al.  LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial , 2022, Annals of Oncology.

[4]  A. Prat,et al.  A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes , 2022, NPJ breast cancer.

[5]  Yeon-Hee Park,et al.  Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer , 2022, Breast.

[6]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. la Vecchia,et al.  European trends in breast cancer mortality, 1980-2017 and predictions to 2025. , 2021, European journal of cancer.

[8]  A. Prat,et al.  Gene expression profiles of breast cancer metastasis according to organ site , 2021, Molecular oncology.

[9]  G. Curigliano,et al.  Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. , 2021, European journal of cancer.

[10]  P. Bendahl,et al.  PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications , 2021, Cancers.

[11]  A. Chaudhury,et al.  Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Schiff,et al.  Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis , 2021, Cancers.

[13]  A. Guerrero-Zotano,et al.  Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Nuciforo,et al.  Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial , 2020, Clinical Cancer Research.

[15]  T. Nielsen,et al.  The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients , 2020, npj Breast Cancer.

[16]  R. Gomis,et al.  Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade , 2020, Nature Communications.

[17]  Charles M. Perou,et al.  HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[18]  A. Prat,et al.  Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. , 2019, The Lancet. Oncology.

[19]  Zhou Zhu,et al.  Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer , 2019, Clinical Cancer Research.

[20]  G. Hortobagyi,et al.  Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. , 2019, The oncologist.

[21]  S. Loi,et al.  Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Nielsen,et al.  The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer , 2018, Breast Cancer Research.

[23]  L. Chow,et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.

[24]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Perou,et al.  Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. , 2018, Cancer treatment reviews.

[26]  A. Prat,et al.  1727PDistribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies , 2017 .

[27]  C. Perou,et al.  Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. , 2017, Cancer research.

[28]  Xin Hu,et al.  Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study , 2017, Scientific Reports.

[29]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[30]  M. Cheang,et al.  Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. , 2016, JAMA oncology.

[31]  J. Bergh,et al.  Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse , 2016, Molecular oncology.

[32]  E. Mardis,et al.  PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) , 2016, npj Breast Cancer.

[33]  Charles M. Perou,et al.  Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy , 2015, BMC Medicine.

[34]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[35]  S. Ferree,et al.  Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay , 2015, Clinical Cancer Research.

[36]  M. Fernö,et al.  Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  C. Perou,et al.  Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.

[38]  T. Nielsen,et al.  PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients , 2014, Acta oncologica.

[39]  R. Greil,et al.  Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Donald A. Berry,et al.  PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer , 2013, Breast Cancer Research and Treatment.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[43]  E. Mardis,et al.  A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.

[44]  Mark T. W. Ebbert,et al.  Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial , 2012, Clinical Cancer Research.

[45]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[46]  M. Andersson,et al.  Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[48]  Wolfgang Viechtbauer,et al.  Outlier and influence diagnostics for meta‐analysis , 2010, Research synthesis methods.

[49]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.